Quote:

---

It appears there is no desire at this time to advertise to retail investors

---

I agree, but would switch out desire with need ...

Seeing the way things have played out over the past few weeks, it's more telling to go back and read what GC was saying 6, 8 months ago or even longer...


After discussion with several large institutional investment funds, investment bankers and research analysts, it is clear that there are certain requirements that the larger, more seasoned investment community would like to see when an issuer within the development-stage biotechnology space presents itself to the mature capital markets in the United States: - See more at: http://www.thechairmansblog.com/amarantus-bio...WuWoM.dpuf

We believe our approach of assessing an underlying aspect of disease biology and preparing for commercial-launch ahead of a major media push is the correct path so we can maximally capitalize on potential media attention, not only by an increase in the number of interviews I conduct, but most importantly by product sales.

We will be first to market by years. This will allow us to appropriately establish a market for LymPro ahead of others and make LymPro the standard within the space;
Both the Proteomics and Georgetown based tests were identified through an iterative process, with no direct relation to disease biology, whereas LymPro is measuring a specific aspect to disease biology. This significantly improves the potential utility of LymPro as a companion diagnostic, which will ultimately be a massive value driver for any Alzheimer’s blood test;

#C4CT presentation was focused on the scientific community, not the investor community.

Our strategy was successful and we expect significant collaborations to emerge as a result. - See more at: http://www.thechairmansblog.com/amarantus-bio...FvWo6.dpuf

Cheers